BLUE EV/EBITDA Analysis

The current EV/EBITDA of -2.4x means that the enterprise value (total market value plus debt minus cash) is negative relative to earnings before interest, taxes, depreciation, and amortization — effectively, the company has negative operating earnings, so the ratio is inverted and not meaningful as a valuation multiple in the usual sense.

Compared to the healthcare sector median of 13.4x, bluebird bio sits at the 14th percentile of sector peers, meaning it ranks lower than 86% of its peers on this metric. The trend for EV/EBITDA is not available (N/A), with no year-over-year or quarter-over-quarter change to assess because the company reported negative EBITDA in the current period. The combination of a deeply negative level and unavailable trend signals that the company is currently unprofitable on an EBITDA basis, which elevates risk because conventional valuation tools cannot confirm whether the stock is cheap or expensive. This metric contradicts the overall NEUTRAL verdict, as a negative EV/EBITDA typically indicates financial stress or a pre-revenue stage, warranting a more cautious stance rather than a neutral one.

Frequently Asked Questions

Closest Sector Peers